Karina Hermosillo Reséndiz

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Annamaria Colao, Marcello D. Bronstein, Pamela U. Freda et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 389 citations · Full text

Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study

Astrid Breitschaft, Ke Hu, Karina Hermosillo Reséndiz et al. · Diabetes Research and Clinical Practice · 2013 · 112 citations

Metabolic Syndrome, Diabetes Management, Metabolic Disorder +9

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Michael C. Sheppard, Marcello D. Bronstein, Pamela U. Freda et al. · Pituitary · 2014 · 81 citations · Full text

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Stephan Petersenn, Andrew J. Farrall, Christophe De Block et al. · Pituitary · 2013 · 58 citations · Full text

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

Edward M. Wolin, Ke Hu, Gareth Hughes et al. · Cancer Chemotherapy and Pharmacology · 2013 · 43 citations · Full text